BUSAN, South Korea--(BUSINESS WIRE)--NexThera Co., Ltd. (CEO SaeGwang Park) announced that it has submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug ...
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...
Immuneering Corporation IMRX announced that it has submitted an investigational new drug (IND) application to the FDA to begin a clinical study on its lead product candidate IMM-1-104 for the ...
GT Biopharma Inc. has filed an IND application with the FDA for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for the treatment of B7-H3-expressing solid tumor cancers. Pending ...
Circle Pharma Inc. has submitted an IND application to the FDA for CID-078, a first-in-class cyclin A/B RxL inhibitor. Pending approval, the company plans to initiate a phase I trial in patients with ...
HOUSTON, TX / ACCESS Newswire / March 4, 2026 / BrYet US, Inc. (“BrYet”) – a biotechnology innovator focused on developing curative therapies for advanced cancers – announced today that it has filed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results